<?xml version="1.0" encoding="UTF-8"?>
<p>Moreover, multiple countries have been able to make treatment accessible to the broader population by successfully negotiating with patent holders (eg Australia), making use of patent licenses either available directly from the patent owner or those held by the Medicines Patent Pool (eg Rwanda),
 <xref rid="liv14222-bib-0086" ref-type="ref">86</xref> or using TRIPS flexibilities to circumvent patent barriers to accessing lower priced generic DAAs (eg Malaysia, see Table 
 <xref rid="liv14222-tbl-0004" ref-type="table">4</xref> and Appendix 
 <xref rid="liv14222-sup-0001" ref-type="supplementary-material">S1</xref>).
 <xref rid="liv14222-bib-0087" ref-type="ref">87</xref>
</p>
